Research Article
Lumpectomy Combined with Adjuvant Radiotherapy Could Be a Treatment Option for Primary Squamous Cell Carcinoma of the Breast
Table 1
Baseline characteristics according to treatment regimens.
| | Characteristics | n | MAST (%) | MAST + RT (%) | LUMP (%) | LUMP + RT (%) | p |
| | Year of study | | 1983–1993 | 56 | 38 (15.0%) | 6 (7.7%) | 7(8.0%) | 5 (5.2%) | 0.012 | | 1994–2004 | 209 | 103 (40.6%) | 28 (35.9%) | 29 (33.3%) | 49(51.0%) | | 2005–2016 | 250 | 113 (44.5%) | 44 (56.4%) | 51 (58.6%) | 42 (43.8%) | | Age (years) | | ≤50 | 93 | 31 (12.2%) | 23 (29.5%) | 17 (19.5%) | 22 (22.9%) | 0.002 | | >50 | 422 | 223 (87.8%) | 55 (70.5%) | 70 (80.5%) | 74 (77.1%) | | Race | | Black | 59 | 29 (11.4%) | 8 (10.3%) | 10 (11.5%) | 12 (12.5%) | 0.99 | | White | 433 | 212 (83.5%) | 67 (85.9%) | 73 (83.9%) | 81 (84.4%) | | Others | 23 | 13 (5.1%) | 3 (3.8%) | 4 (4.6%) | 3 (3.1%) | | TNM stage | | I | 95 | 29 (11.4%) | 2 (2.5%) | 34 (39.1%) | 30 (31.3%) | <0.001 | | II | 243 | 131 (51.6%) | 37 (47.4%) | 32 (36.8%) | 43 (44.8%) | | III | 91 | 47 (18.5%) | 30 (38.5%) | 5 (5.7%) | 9 (0.4%) | | Unknown | 86 | 47 (18.5%) | 9 (11.5%) | 16 (18.4%) | 14 (14.6%) | | Tumor stage (n = 429) | | T1 | 108 | 35 (13.8%) | 4 (5.1%) | 35 (40.2%) | 34 (35.4%) | <0.001 | | T2 | 195 | 105 (41.3%) | 27 (34.6%) | 29 (33.3%) | 34 (35.4%) | | T3 | 75 | 40 (15.7%) | 20 (25.6%) | 3 (3.4%) | 12 (12.5%) | | T4 | 51 | 27 (10.6%) | 18 (23.1%) | 4 (4.6%) | 2 (2.1%) | | Unknown | 86 | 47 (18.5%) | 9 (11.5%) | 16 (18.3%) | 14 (14.6%) | | Nodal stage | | N0 | 322 | 156 (61.4%) | 39 (50%) | 62 (71.3%) | 65 (67.7%) | 0.002 | | N1 | 72 | 32 (12.6%) | 22 (28.2%) | 6 (6.9%) | 12 (12.5%) | | N2 | 21 | 11 (4.3%) | 7 (9.0%) | 1 (1.1%) | 2 (2.1%) | | N3 | 10 | 6 (2.4%) | 1 (1.3%) | 0 | 3 (3.1%) | | Unknown | 90 | 49 (19.3%) | 9 (11.5%) | 18 (20.7%) | 14 (14.6%) | | ER status | | Positive | 71 | 39 (15.4%) | 11 (14.1%) | 9 (10.3%) | 12 (12.5%) | 0.01 | | Negative | 303 | 139 (54.7%) | 53 (67.9%) | 44 (50.6%) | 67 (69.8%) | | Unknown | 141 | 76 (29.9%) | 14 (17.9%) | 34 (39.1%) | 17 (17.7%) | | PR status | | Positive | 42 | 15 (5.9%) | 11 (14.1%) | 6 (6.9%) | 10 (10.4%) | 0.01 | | Negative | 327 | 159 (62.6%) | 53 (67.9%) | 48 (55.2%) | 67 (69.8%) | | Unknown | 146 | 80 (31.5%) | 14 (17.9%) | 33 (37.9%) | 19 (19.8%) | | Grade | | Well-differentiated | 50 | 22 (33.3%) | 7 (33.3%) | 14 (41.2%) | 7 (24.1%) | 0.29 | | Moderately differentiated | 122 | 66 (66.7%) | 14 (66.7%) | 20 (58.8%) | 22 (75.9%) | | Poor or undifferentiated | 253 | 117 (70.5%) | 47 (82.5%) | 40 (75.5%) | 49 (73.1%) | | Unknown | 90 | 49 (29.5%) | 10 (17.5%) | 13 (24.5%) | 18 (26.9%) | | Chemotherapy | | Yes | 206 | 86 (33.9%) | 54 (69.2%) | 17 (19.5%) | 49 (51.0%) | <0.001 | | No/unknown | 309 | 168 (66.1%) | 24 (30.8%) | 70 (80.5%) | 47 (49.0%) |
|
|
MAST, mastectomy; LUMP, lumpectomy; RT, radiotherapy; ER, estrogen receptor; PR, progesterone receptor.
|
